Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Participants of the Healthy Group must meet the following criteria to be eligible for participation in the study:~1. Healthy male or female, greater or equal to 20 and less than or equal to 70 years of age;~2. Willing to comply with the protocol requirements;~3. Willing to provide informed consent.~Participants of the Obese/Type 2 Diabetes Group must meet the following criteria to be eligible for participation in the study:~1. Male or female, greater or equal to 20 and less than or equal to 70 years of age;~2. Presence of clinically diagnosed Type 2 Diabetes, and/or a body mass index (BMI) \> 30;~3. Willing to comply with the protocol requirements;~4. Willing to provide informed consent.~Participants of the Vascular Disease Group must meet the following criteria to be eligible for participation in the study:~1. Male or female, greater or equal to 20 and less than or equal to 70 years of age;~2. Documented evidence of atherosclerosis as manifested by one of the following:~   1. documented myocardial infarction;~  2. documented CAD as defined as \>70% stenosis of an epicardial coronary artery;~  3. documented PAD including those with claudication as defined by an ankle brachial index of \<0.9;~  4. angiographically documented carotid or lower limb stenosis of \>50%~3. Willing to comply with the protocol requirements;~4. Willing to provide informed consent -~Exclusion Criteria:~Participants of the Healthy Group will be excluded if they have any of the following:~1. Presence of a clinically diagnosed disease affecting the circulatory, respiratory, immune, skeletal, urinary, muscular, endocrine, digestive, nervous or reproductive system that requires medical treatment;~2. Cigarette/cigar smoking, current or within the last 6 months;~3. Current (within the last 30 days) bacterial, viral or fungal infection;~4. Taking any prescribed medication (with the exception of birth control or HRT) within the last 3 months or over-the-counter medication within the past 72 h;~5. Pregnancy;~6. Amputation or malformation of any limb or extremity (fingers, leg, or arm) which would impede the placement of sensors, probes, or blood pressure cuffs.~Participants of the Obese/Type 2 Diabetes Group will be excluded if they have any of the following:~1. Documented evidence of atherosclerosis as manifested by one of the following:~   1. documented myocardial infarction;~  2. documented CAD as defined as \>70% stenosis of an epicardial coronary artery;~  3. documented PAD including those with claudication as defined by an ankle brachial index of \<0.9;~  4. angiographically documented carotid or lower limb stenosis of \>50%~  5. having had a documented previous intervention for CAD or PAD.~2. Cigarette/cigar smoking, current or within the last 6 months;~3. Current (within the last 30 days) bacterial, viral or fungal infection;~4. Taking over-the-counter medication within the past 72 h;~5. Pregnancy;~6. Amputation or malformation of any limb or extremity (fingers, leg, or arm) which would impede the placement of sensors, probes, or blood pressure cuffs.~Participants of the Vascular Disease Group will be excluded if they have any of the following:~1. Cigarette/cigar smoking, current or within the last 6 months;~2. Current (within the last 30 days) bacterial, viral or fungal infection;~3. Taking over-the-counter medication within the past 72 h;~4. Pregnancy;~5. Amputation or malformation of any limb or extremity (fingers, leg, or arm) which would impede the placement of sensors, probes, or blood pressure cuffs.~6. Having had a documented previous intervention for CAD or PAD

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- ASI Device (Type: EXPERIMENTAL): Study Participants will attend the research clinic one time (one visit) for the vascular testing. Each instrument/assessment will be run sequentially starting with the Arterial Stiffness Screening Device, then followed by SphygmoCor system, which will then be followed by the CR-2000 CV Profiler, then finally the VP-1000.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy